Contribute Try STAT+ Today

File this under “three strikes and you’re out!”

Twice last fall, the House Committee on Oversight and Government Reform asked Mylan Pharmaceuticals to submit documents about EpiPen pricing, but to date, the company has provided precious few. So last Friday, the committee warned Mylan attorneys that, if the company does not comply, a subpoena may be issued for Mylan execs to testify and produce the documents.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • gag me why are they allowed to exclude the government settlement from their bonus calculation? This is nothing more than a catch up of a business expense or adjustment downward to revenue that should have taken place years ago.

Comments are closed.